Aclaris Therapeutics, Inc.
ACRS
$1.34
-$0.15-10.07%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 111.94% | 57.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 111.94% | 57.12% | |||
| Cost of Revenue | 1,052.18% | -66.89% | |||
| Gross Profit | -3,967.81% | 110.30% | |||
| SG&A Expenses | -12.37% | 18.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 66.09% | -9.10% | |||
| Operating Income | -45.49% | 23.57% | |||
| Income Before Tax | -1,172.77% | 30.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,172.77% | 30.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,172.77% | 30.95% | |||
| EBIT | -45.49% | 23.57% | |||
| EBITDA | -46.24% | 23.95% | |||
| EPS Basic | -853.06% | 31.02% | |||
| Normalized Basic EPS | -20.88% | 37.21% | |||
| EPS Diluted | -854.19% | 31.02% | |||
| Normalized Diluted EPS | -20.88% | 37.21% | |||
| Average Basic Shares Outstanding | 33.52% | 0.13% | |||
| Average Diluted Shares Outstanding | 33.52% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
